有毛細胞性白血病(Hairy Cell Leukemia):治療薬開発パイプライン動向(2016年下半期版)

Global Markets Directが発行した調査報告書(DATA70209351)
◆英語タイトル:Hairy Cell Leukemia - Pipeline Review, H2 2016
◆商品コード:DATA70209351
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2016年10月30日
◆ページ数:93
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における有毛細胞性白血病(Hairy Cell Leukemia)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・有毛細胞性白血病(Hairy Cell Leukemia)の概要
・有毛細胞性白血病(Hairy Cell Leukemia)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・有毛細胞性白血病(Hairy Cell Leukemia)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・有毛細胞性白血病(Hairy Cell Leukemia)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・有毛細胞性白血病(Hairy Cell Leukemia)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Hairy Cell Leukemia – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hairy Cell Leukemia – Pipeline Review, H2 2016, provides an overview of the Hairy Cell Leukemia (Oncology) pipeline landscape.

Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Hairy Cell Leukemia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hairy Cell Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 1, 1, 2 and 1 respectively.Hairy Cell Leukemia.

Hairy Cell Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hairy Cell Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hairy Cell Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hairy Cell Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hairy Cell Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hairy Cell Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hairy Cell Leukemia Overview 7
Therapeutics Development 8
Pipeline Products for Hairy Cell Leukemia – Overview 8
Hairy Cell Leukemia – Therapeutics under Development by Companies 9
Hairy Cell Leukemia – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Hairy Cell Leukemia – Products under Development by Companies 14
Hairy Cell Leukemia – Companies Involved in Therapeutics Development 15
AbbVie Inc 15
ARA Healthcare Pvt. Ltd. 16
Astellas Pharma Inc. 17
Biogenomics Limited 18
F. Hoffmann-La Roche Ltd. 19
Incyte Corporation 20
Juno Therapeutics Inc. 21
MedImmune LLC 22
Novartis AG 23
Hairy Cell Leukemia – Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
(dezapelisib + itacitinib adipate) – Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
AGS-67E – Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
ARABS-4 – Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
dabrafenib mesylate + trametinib dimethyl sulfoxide – Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
dezapelisib – Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ibrutinib – Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
INCB-50465 – Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
interferon alfa-2a – Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
interferon alfa-2b – Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
interferon alfa-2b – Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
itacitinib adipate – Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
JCAR-015 – Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
moxetumomab pasudotox – Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
vemurafenib – Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Hairy Cell Leukemia – Dormant Projects 88
Hairy Cell Leukemia – Discontinued Products 89
Hairy Cell Leukemia – Product Development Milestones 90
Featured News & Press Releases 90
Oct 09, 2016: ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumors 90
May 16, 2013: AstraZeneca’s MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox 91
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 92
Disclaimer 93

List of Tables
Number of Products under Development for Hairy Cell Leukemia, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Comparative Analysis by Unknown Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Hairy Cell Leukemia - Pipeline by AbbVie Inc, H2 2016 15
Hairy Cell Leukemia - Pipeline by ARA Healthcare Pvt. Ltd., H2 2016 16
Hairy Cell Leukemia - Pipeline by Astellas Pharma Inc., H2 2016 17
Hairy Cell Leukemia - Pipeline by Biogenomics Limited, H2 2016 18
Hairy Cell Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 19
Hairy Cell Leukemia - Pipeline by Incyte Corporation, H2 2016 20
Hairy Cell Leukemia - Pipeline by Juno Therapeutics Inc., H2 2016 21
Hairy Cell Leukemia - Pipeline by MedImmune LLC, H2 2016 22
Hairy Cell Leukemia - Pipeline by Novartis AG, H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Assessment by Combination Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Hairy Cell Leukemia - Dormant Projects, H2 2016 88
Hairy Cell Leukemia - Discontinued Products, H2 2016 89

List of Figures
Number of Products under Development for Hairy Cell Leukemia, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Top 10 Targets, H2 2016 26
Number of Products by Stage and Top 10 Targets, H2 2016 26
Number of Products by Top 10 Mechanism of Actions, H2 2016 28
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 28
Number of Products by Routes of Administration, H2 2016 30
Number of Products by Stage and Routes of Administration, H2 2016 30
Number of Products by Molecule Types, H2 2016 32
Number of Products by Stage and Molecule Types, H2 2016 32

【レポートのキーワード】

有毛細胞性白血病(Hairy Cell Leukemia)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 有毛細胞性白血病(Hairy Cell Leukemia):治療薬開発パイプライン動向(2016年下半期版)(Hairy Cell Leukemia - Pipeline Review, H2 2016)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆